Spencer board OKs buyout

Spencer Pharmaceutical announced today that its board of directors is in favor of the buyout offer at $0.97 per share. The company has requested details from the acquirer as well as timeline and have requested that funds be transferred to an independent escrow agent. The company expects to release the name of the private equity fund on or before Nov. 19, and file appropriate supplemental information on the alternative reporting system of the OTC Markets. Spencer release

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."